Building on the success of the 2024 summit, the 7th Exosome Based Therapeutic Development Summit returns with a refreshed program, with data-driven insights from those pioneering the field who are dedicated to the clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications.
Recent scientific developments, particularly in antibody engineering, have led to numerous innovations in cancer immunotherapy and one of the most promising innovations has been the development of bispecific antibodies, as bispecific drugs make huge waves in multiple myeloma and lymphoma, so much so that they threaten cell therapy in multiple myeloma.
Creative Biolabs has recently made upgrades to its CAR-T preclinical research, further enhancing the safety and functional evaluation of these therapies.
By Philippa Clark, Director of Business Development, One Nucleus
Cambridge Tech Week is a global tech gathering designed to unite the brightest minds - visionaries, world-leading experts, and strategic investors - to drive growth, collaboration, and transformative innovation across the tech ecosystem.
Devens, MA, USA — Veranova, a global leader in the development and manufacture of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, announced today that a routine current Good Manufacturing Practice (cGMP) surveillance inspection of Veranova’s Devens, Massachusetts site, completed by the Food and Drug Administration (FDA) New England District on July 31, 2025, concluded without any Form 483s and with a “No Action Indicated” (NAI) classification. This result demonstrates Veranova’s commitment to driving the highest standards of qu
Need to move faster from preclinical to first-in-human? CMC timelines for IND/CTA submissions can make or break a development plan. In this webinar, our CMC and regulatory experts will share how to avoid common bottlenecks and build submission strategies aligned with both FDA and EMA expectations.
o What typically causes delays when filing in both the US and EU?
o How can early CMC planning shorten your submission timeline?
o What support can you tap into from regulators today?
A fantastic opportunity has arisen for a Principal Scientist – Discovery & Translational Biology to join a high-potential drug-development start-up, who are focussed on developing new oncology therapeutics that significantly improve overall survival for patients with a high unmet need. Our client is at the cutting edge of oncology therapeutics, triggering a new wave in target discovery by using proprietary algorithms to identify novel protein fingerprints from a comprehensive membrane protein database.
We are currently looking for a Senior GMP Production Scientist to join a leading biopharmaceutical CDMO based in the South West of the UK to join their team.
Our client specialises in GMP manufacturing of advanced therapy and biologic products. As a Senior GMP Production Scientist, you will take the lead in supervising GMP manufacturing operations for a range of clinical products. This includes overseeing production teams, supporting technology transfer, and ensuring compliance across ATMP and biologics projects.
We are recruiting a Principal Scientist, Non-Clinical PKPD, to join a leading Pharmaceutical company based in the Berkshire area for 12 months. As the Principal Scientist, Non-Clinical PKPD, you will be responsible for driving the quantitative integrated strategy of pharmacokinetics and pharmacology to bring differentiated solutions to patients.
KEY DUTIES AND RESPONSIBILITIES:
Your duties as the Principal Scientist, Non-Clinical PKPD will be varied however the key duties and responsibilities are as follows: